PRAXIS PRECISION MEDICINES INC (PRAX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PRAX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRAX | [] | ["Audit Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZTS | Former Chief Financial Officer of Wyeth; Independent Director; Chair | 68 | ["Former Chief Financial Officer of Wyeth","Over 20 years of leadership and financial management experience in global healthcare and pharmaceuticals","Exceptional financial and accounting expertise","Knowledge of reporting requirements and disclosure rules","Audit committee responsibilities","Institutional knowledge as chair of the Audit Committee","Expertise in working with internal and external audit teams","Navigating complex financial and compliance matters","Financially Literate","Audit committee financial expert"] | ["Audit","Corporate Governance","Audit Committee","Corporate Governance Committee"] | 2026 |
| RPRX | Independent Director; Chair | 68 | ["Former CFO, Wyeth","Leadership","Finance / Accounting","Business Strategy","Technology/Cybersecurity","Risk Management","Managing Director of G9 Capital Group LLC since January 2010","Member of the Investment Committee of Royalty Pharma (2014 to June 2020)","Various senior positions at Wyeth, including Chief Financial Officer from 1989 to 2010","Started career with Arthur Andersen & Company","Chair of Audit Committee","Selected for vast financial and accounting expertise","Broad knowledge of global business operations, finance, leadership, strategy and risk management","Qualified as an audit committee financial expert","financial expert","audit committee experience"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Gregory Norden has served as a member of our Board of Directors since March 2019. Mr. Norden is the former Chief Financial Officer of Wyeth Pharmaceuticals Inc. and has served as the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate advisory services, since 2010. Mr. Norden currently serves on the boards of directors of Zoetis Inc. (NYSE: ZTS) and Royalty Pharma plc (NASDAQ: RPRX). Mr. Norden previously served on the boards of directors of Human Genome Sciences, Inc., Univision, Welch Allyn and NanoString Technologies, Inc. Mr. Norden received a B.S. in Management and Economics from the State University of New York at Plattsburgh and an M.S. in Accounting from LIU Post. We believe Mr. Norden is qualified to serve on our Board of Directors because of his background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, as well as his public company board experience.